← ANALYST RATINGS · TIPRANKS
Lakefront Biotherapeutics (LKFT): analyst forecast and price target
Analyst consensus
Moderate Buy1 Buy0 Hold0 Sell
Ratings of 1 analysts in the last 3 months · top analysts only12-month forecast
Based on 1 price targets given in the last 3 months, the average target is $45.00, the highest $45.00, the lowest $45.00. The average is +50.5% from the last price of $29.90.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Judah Frommer★★★★★★★★★★#2495 · hits 56% · avg +5.3% | Morgan Stanley | $26.00 | Hold | −13.0% | Assigned | 05.10.26on TipRanks 08:35 | −0.2%next day −1.2% · 5 days −0.2% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $32.00 → $34.00+6.2% | Buy | +13.7% | Reiterated | 25.09.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $32.00 → $34.00+6.2% | Buy | +13.7% | Reiterated | 25.09.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $31.00 → $34.00+9.7% | Hold | +13.7% | Reiterated | 25.09.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $30.00 → $32.00+6.7% | Hold | +7.0% | Reiterated | 25.09.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $31.00 → $34.00+9.7% | Buy | +13.7% | Upgrade | 25.09.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $32.00 → $35.00+9.4% | Buy | +17.1% | Upgrade | 25.09.26on TipRanks 00:05 | — | |
| Brian Abrahams★★★★★★★★★★#481 · hits 57% · avg +15.1% | RBC Capital | $26.00 → $45.00+73.1% | Buy | +50.5% | Upgrade | 23.09.26on TipRanks 04:50 | +2.5%next day −1.1% · 5 days −2.8% | ↗ |
| Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% | Bank of America Securities | $25.00 → $28.00+12.0% | Sell | −6.4% | Reiterated | 06.11.25on TipRanks May 13 07:35 | +5.5%next day +1.0% · 5 days +0.7% | ↗ |
| Faisal Khurshid★★★★★★★★★★#51 · hits 66% · avg +74.6% | Jefferies | $29.00 → $40.00+37.9% | Buy | +33.8% | Upgrade | 22.10.25on TipRanks May 13 07:35 | +1.9%next day −0.1% · 5 days −5.9% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Lakefront Biotherapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 05.10.26: target $35.50 at a price of $29.37 (+20.9%); now: $35.50 at $29.90 (+18.7%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Hold | 2 | 2 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 12.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.83 (from $-1.88 to $0.27). Last quarter: $0.03.
Sales
Next quarter’s sales estimate — $8M (from $1M to $13M). Last quarter: $14M.
Best top-analyst consensus in the sector · Healthcare
About Lakefront Biotherapeutics
- CEO: Henry O. Gosebruch
- Employees: 452
- SchaliEnhoevedreef 20 T, Mechelen, 2800, BE
- lakefrontbio.com
Lakefront Biotherapeutics NV, formerly Galapagos NV, is a biotechnology company that focuses on transforming patient outcomes through scientific innovation. It is dedicated to building a pipeline of medicines for patients with serious diseases in therapeutic areas of unmet need, prioritizing oncology and immunology & inflammation programs. The company's clinical-stage portfolio is anchored by potential first-in-class treatments for autoimmune diseases.
Data from the stock’s TipRanks forecast page, read 213 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗